^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-15 superagonist

    Related drugs:
    2d
    INTERRUPT_LC: A Study to Assess Anktiva in Patients With Long Covid-19. (clinicaltrials.gov)
    P2, N=20, Recruiting, ImmunityBio, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    4d
    Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, ImmunityBio, Inc.
    New P2 trial
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • AgenT-797
    6d
    ResQ108B-PANC: Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, ImmunityBio, Inc.
    New P1 trial
    |
    gemcitabine • albumin-bound paclitaxel • Anktiva (nogapendekin alfa inbakicept-pmln) • sotevtamab (AB-16B5) • zabinostat (CXD101)
    13d
    Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=20, Recruiting, ImmunityBio, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • Anktiva (nogapendekin alfa inbakicept-pmln) • CD19.t-haNK
    18d
    IL 15 enhances preclinical efficacy of anti-core 1 O-glycans monoclonal antibody NEO-201 against human endometrial and ovarian cancer. (PubMed, Front Immunol)
    A previous study showed that IL-15 superagonist complex (N-803) enhanced ADCC activity mediated by NEO-201 in vitro against several human carcinoma cells, by modulating NK cells activation and cytotoxicity. In this study we demonstrated that IL-15 enhanced ADCC mediated by NEO-201 in vitro against human endometrial and ovarian cancer cell lines expressing NEO-201 target antigen, and that the combination of IL-15 and NEO-201, using purified human NK cells as effectors, had a modest effect in prolonging the survival of mice bearing human ovarian cancer, compared to IL-15 or NEO-201 alone. The ability of IL-15 to enhance NEO-201 efficacy, with NK cells as effectors, supports the hypothesis of combining NEO-201 and IL-15 with NK cell therapy (i.e. IL-15-secreting CAR-NK cells with a longer IL-15 in vivo half-life and stronger NK activity) for the treatment of gynecological cancers expressing O-glycans recognized by NEO-201.
    Preclinical • Journal
    |
    IL15 (Interleukin 15)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • NEO-201
    1m
    BGB-R046-101: A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors (clinicaltrials.gov)
    P1, N=75, Active, not recruiting, BeOne Medicines | Recruiting --> Active, not recruiting
    Enrollment closed • First-in-human
    |
    Tevimbra (tislelizumab-jsgr)
    1m
    QUILT-2.005: A Study Testing a New Drug (ALT-803) With BCG to Treat Early-Stage Bladder Cancer (2025-521223-78-00)
    P1/2, N=50, Not yet recruiting, Immunitybio Inc.
    New P1/2 trial
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • Tice BCG (live attenuated bacillus Calmette-Guerin)
    2ms
    CARMEN-803: N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1, N=13, Not yet recruiting, University of Utah | Trial completion date: Sep 2031 --> Dec 2031 | Trial primary completion date: Sep 2030 --> Dec 2030
    Trial completion date • Trial primary completion date
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    2ms
    FLINN: First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=26, Not yet recruiting, Washington University School of Medicine
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Anktiva (nogapendekin alfa inbakicept-pmln)
    3ms
    A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=130, Recruiting, Suzhou Forlong Biotechnology Co., Ltd | Not yet recruiting --> Recruiting | Initiation date: Sep 2025 --> Jan 2026
    Enrollment open • Trial initiation date
    3ms
    A Study of FL115 Monotherapy in Unresectable or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Suzhou Forlong Biotechnology Co., Ltd | Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2025 --> Jun 2026
    Enrollment closed • Trial primary completion date
    3ms
    First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study (clinicaltrials.gov)
    P1, N=18, Completed, Suzhou Forlong Biotechnology Co., Ltd | Recruiting --> Completed | Trial completion date: Sep 2026 --> Sep 2025 | Trial primary completion date: May 2026 --> Feb 2025
    Trial completion • Trial completion date • Trial primary completion date • First-in-human
    |
    PD-L1 (Programmed death ligand 1)